JP2016510054A5 - - Google Patents

Download PDF

Info

Publication number
JP2016510054A5
JP2016510054A5 JP2015560654A JP2015560654A JP2016510054A5 JP 2016510054 A5 JP2016510054 A5 JP 2016510054A5 JP 2015560654 A JP2015560654 A JP 2015560654A JP 2015560654 A JP2015560654 A JP 2015560654A JP 2016510054 A5 JP2016510054 A5 JP 2016510054A5
Authority
JP
Japan
Prior art keywords
fibrosis
liver
burns
systemic
ischemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015560654A
Other languages
English (en)
Other versions
JP2016510054A (ja
JP6514119B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/054107 external-priority patent/WO2014135507A1/en
Publication of JP2016510054A publication Critical patent/JP2016510054A/ja
Publication of JP2016510054A5 publication Critical patent/JP2016510054A5/ja
Application granted granted Critical
Publication of JP6514119B2 publication Critical patent/JP6514119B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (4)

  1. 疼痛、アテローム性動脈硬化症、加齢黄斑変性症、糖尿病性網膜症、緑内障、網膜静脈閉塞、未熟児網膜症、眼虚血症候群、地図状萎縮、糖尿病、炎症、炎症性腸疾患、虚血−再灌流傷害、急性肝不全、肝線維症、肺線維症、腎線維症、全身性線維症、急性移植片拒絶反応、慢性移植腎症、糖尿病性腎症、糸球体腎症、心筋症、心不全、心筋虚血、心筋梗塞、全身性硬化症、熱傷、火傷、肥厚性瘢痕、ケロイド、歯肉炎、発熱、肝臓の硬変又は腫瘍、骨量の制御、神経変性、筋萎縮性側索硬化症、多発性硬化症、卒中、一過性脳虚血発作又はブドウ膜炎の治療又は予防のための、請求項1〜13のいずれか一項に記載の化合物の使用。
  2. 疼痛、アテローム性動脈硬化症、加齢黄斑変性症、糖尿病性網膜症、緑内障、網膜静脈閉塞、未熟児網膜症、眼虚血症候群、地図状萎縮、糖尿病、炎症、炎症性腸疾患、虚血−再灌流傷害、急性肝不全、肝線維症、肺線維症、腎線維症、全身性線維症、急性移植片拒絶反応、慢性移植腎症、糖尿病性腎症、糸球体腎症、心筋症、心不全、心筋虚血、心筋梗塞、全身性硬化症、熱傷、火傷、肥厚性瘢痕、ケロイド、歯肉炎、発熱、肝臓の硬変又は腫瘍、骨量の制御、神経変性、筋萎縮性側索硬化症、多発性硬化症、卒中、一過性脳虚血発作又はブドウ膜炎の治療又は予防のための医薬の調製のための、請求項1〜13のいずれか一項に記載の化合物の使用。
  3. 疼痛、アテローム性動脈硬化症、加齢黄斑変性症、糖尿病性網膜症、緑内障、網膜静脈閉塞、未熟児網膜症、眼虚血症候群、地図状萎縮、糖尿病、炎症、炎症性腸疾患、虚血−再灌流傷害、急性肝不全、肝線維症、肺線維症、腎線維症、全身性線維症、急性移植片拒絶反応、慢性移植腎症、糖尿病性腎症、糸球体腎症、心筋症、心不全、心筋虚血、心筋梗塞、全身性硬化症、熱傷、火傷、肥厚性瘢痕、ケロイド、歯肉炎、発熱、肝臓の硬変又は腫瘍、骨量の制御、神経変性、筋萎縮性側索硬化症、多発性硬化症、卒中、一過性脳虚血発作又はブドウ膜炎の治療又は予防のための、請求項1〜13のいずれか一項に記載の化合物。
  4. 疼痛、アテローム性動脈硬化症、加齢黄斑変性症、糖尿病性網膜症、緑内障、網膜静脈閉塞、未熟児網膜症、眼虚血症候群、地図状萎縮、糖尿病、炎症、炎症性腸疾患、虚血−再灌流傷害、急性肝不全、肝線維症、肺線維症、腎線維症、全身性線維症、急性移植片拒絶反応、慢性移植腎症、糖尿病性腎症、糸球体腎症、心筋症、心不全、心筋虚血、心筋梗塞、全身性硬化症、熱傷、火傷、肥厚性瘢痕、ケロイド、歯肉炎、発熱、肝臓の硬変又は腫瘍、骨量の制御、神経変性、筋萎縮性側索硬化症、多発性硬化症、卒中、一過性脳虚血発作又はブドウ膜炎の治療又は予防のための方法であって、それを必要とする患者に有効量の請求項1〜13のいずれか一項に定義される化合物を投与することを含む方法。
JP2015560654A 2013-03-07 2014-03-04 新規ピラゾール誘導体 Active JP6514119B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13158233 2013-03-07
EP13158233.0 2013-03-07
PCT/EP2014/054107 WO2014135507A1 (en) 2013-03-07 2014-03-04 Novel pyrazol derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018229203A Division JP2019055986A (ja) 2013-03-07 2018-12-06 新規ピラゾール誘導体

Publications (3)

Publication Number Publication Date
JP2016510054A JP2016510054A (ja) 2016-04-04
JP2016510054A5 true JP2016510054A5 (ja) 2017-04-06
JP6514119B2 JP6514119B2 (ja) 2019-05-15

Family

ID=47827068

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015560654A Active JP6514119B2 (ja) 2013-03-07 2014-03-04 新規ピラゾール誘導体
JP2018229203A Pending JP2019055986A (ja) 2013-03-07 2018-12-06 新規ピラゾール誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018229203A Pending JP2019055986A (ja) 2013-03-07 2018-12-06 新規ピラゾール誘導体

Country Status (35)

Country Link
US (2) US9512132B2 (ja)
EP (1) EP2964646B1 (ja)
JP (2) JP6514119B2 (ja)
KR (2) KR102369407B1 (ja)
CN (1) CN105143220B (ja)
AR (1) AR094978A1 (ja)
AU (1) AU2014224784B2 (ja)
BR (1) BR112015020795B1 (ja)
CA (1) CA2897513C (ja)
CL (1) CL2015002387A1 (ja)
CR (1) CR20150447A (ja)
CY (1) CY1118950T1 (ja)
DK (1) DK2964646T3 (ja)
EA (1) EA027935B1 (ja)
ES (1) ES2629751T3 (ja)
HK (1) HK1213258A1 (ja)
HR (1) HRP20170919T1 (ja)
HU (1) HUE034831T2 (ja)
IL (1) IL240327B (ja)
LT (1) LT2964646T (ja)
MA (1) MA38403A1 (ja)
MX (1) MX363727B (ja)
MY (1) MY176797A (ja)
NZ (1) NZ710052A (ja)
PE (1) PE20151539A1 (ja)
PH (1) PH12015501843B1 (ja)
PL (1) PL2964646T3 (ja)
PT (1) PT2964646T (ja)
RS (1) RS56148B1 (ja)
SG (1) SG11201507168XA (ja)
SI (1) SI2964646T1 (ja)
TW (1) TWI609866B (ja)
UA (1) UA118666C2 (ja)
WO (1) WO2014135507A1 (ja)
ZA (1) ZA201505073B (ja)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2964646T1 (sl) * 2013-03-07 2017-08-31 F. Hoffmann-La Roche Ag Novi derivati pirazola
EA027569B1 (ru) 2013-03-26 2017-08-31 Ф.Хоффманн-Ля Рош Аг Производные пиридина
WO2014177490A1 (en) 2013-05-02 2014-11-06 F. Hoffmann-La Roche Ag Purine derivatives as cb2 receptor agonists
SG11201509029PA (en) 2013-05-02 2015-12-30 Hoffmann La Roche Pyrrolo[2,3-d]pyrimidine derivatives as cb2 receptor agonists
HUE055201T2 (hu) 2013-09-06 2021-11-29 Hoffmann La Roche Triazolo[4,5-D]pirimidin-származékok mint CBB2-receptor-antagonisták
CA2979534A1 (en) * 2015-03-13 2016-09-22 Abbvie Inc. (indazol-4-yl)hexahydropyrrolopyrrolones and method of use
WO2016191935A1 (en) * 2015-05-29 2016-12-08 Merck Sharp & Dohme Corp. 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors
WO2016192083A1 (en) 2015-06-04 2016-12-08 Merck Sharp & Dohme Corp. Dihydropyrazolopyrimidinone compounds as pde2 inhibitors
CN115093418A (zh) 2016-06-23 2022-09-23 豪夫迈·罗氏有限公司 对2型大麻素受体具有亲和力的[1,2,3]三唑并[4,5-d]嘧啶衍生物
CN109415366B (zh) 2016-06-23 2022-02-22 豪夫迈·罗氏有限公司 [1,2,3]三唑并[4,5-d]嘧啶衍生物
WO2018015088A1 (en) 2016-06-23 2018-01-25 F. Hoffmann-La Roche Ag Novel [1,2,31triazolo[4,5-d]pyrimidine derivatives
WO2017220544A1 (en) 2016-06-23 2017-12-28 F. Hoffmann-La Roche Ag Novel[1,2,3]triazolo[4,5-d]pyrimidine derivatives
JP7331921B2 (ja) 2019-03-25 2023-08-23 株式会社ニコン 細胞操作システム及び細胞操作方法
CN116438200A (zh) 2020-09-10 2023-07-14 普雷西里克斯公司 针对fap的抗体片段
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting
CN115246832B (zh) * 2022-06-15 2024-05-24 深圳湾实验室 一类去泛素化酶usp25和usp28靶向抑制剂及制备和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2980677A (en) * 1961-04-18 Certificate of correction
JP2004502642A (ja) * 2000-02-11 2004-01-29 ブリストル−マイヤーズ スクイブ カンパニー カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用
EP1492784A4 (en) 2002-03-28 2006-03-29 Merck & Co Inc SUBSTITUTED 2,3-DIPHENYLPYRIDINES
DE10219435A1 (de) * 2002-05-02 2003-11-13 Bayer Cropscience Ag Substituierte Pyrazolo-pyrimidin-4-one
AR051596A1 (es) * 2004-10-26 2007-01-24 Irm Llc Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios
WO2009051705A1 (en) 2007-10-18 2009-04-23 Merck & Co., Inc. Substituted 1,2,4-oxadiazoles and analogs thereof as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
WO2010118367A2 (en) * 2009-04-10 2010-10-14 Progenics Pharmaceuticals, Inc. Antiviral pyrimidines
US9321727B2 (en) 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
UA111640C2 (uk) 2011-11-08 2016-05-25 Ф. Хоффманн-Ля Рош Аг ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2
RU2015101818A (ru) 2012-07-04 2016-08-27 Ф.Хоффманн-Ля Рош Аг Новые производные адамантила в качестве агонистов каннабиноидных рецепторов 2
KR20150092232A (ko) 2012-12-07 2015-08-12 에프. 호프만-라 로슈 아게 Cb2 작용제로 유용한 피리딘-2-아마이드
KR20150091080A (ko) 2012-12-07 2015-08-07 에프. 호프만-라 로슈 아게 Cb2 작용제로서 유용한 피리딘-2-아마이드
PT2928882T (pt) 2012-12-07 2017-03-16 Hoffmann La Roche Derivados de pirazina como agonistas do recetor de cb2
PT2928881T (pt) 2012-12-07 2018-05-07 Hoffmann La Roche Novos derivados de piridina
SI2964646T1 (sl) * 2013-03-07 2017-08-31 F. Hoffmann-La Roche Ag Novi derivati pirazola

Similar Documents

Publication Publication Date Title
JP2016510054A5 (ja)
JP2016034978A5 (ja)
WO2018004283A3 (ko) 글루카곤 유도체, 이의 결합체, 및 이를 포함하는 조성물, 및 이의 치료적 용도
JP2014221779A5 (ja)
MX2015013303A (es) Compuestos heterociclicos utiles para el tratamiento de una enfermedad.
CA2903588C (en) Purine derivatives as cb2 receptor agonists
JP2018507914A5 (ja)
JP2016515522A5 (ja)
JP2014129360A5 (ja)
JP2016518337A5 (ja)
JP2013519675A5 (ja)
JP2013014622A5 (ja)
JP2012193216A5 (ja)
JP2016510326A5 (ja)
JP2016027060A5 (ja)
JP2016520089A5 (ja)
JP2018172440A5 (ja)
JP2017508817A5 (ja)
JP2015516419A5 (ja)
WO2015099838A3 (en) Compositions and methods of treating ocular diseases
JP2013166781A5 (ja)
RU2016127558A (ru) Стероидное соединение для применения в лечении печеночной энцефалопатии
JP2017505809A5 (ja)
JP2014148552A5 (ja)
WO2015009731A3 (en) Azacyclic constrained analogs of fty720